A company called Albany Molecular Research, Inc. (AMRI) has announced that it has a new compound that will be undergoing preclinical testing as an diarrhea-predominant IBS (IBS-D) treatment, with an eye toward the submission of an Investigational New Drug Application with the FDA. What's kind of cool about this new compound - which doesn't appear to even have a name yet - is that it appears to only partially block 5-HT3 receptors, as opposed to the controversial medication Lotronex which completely blocked those important serotonin receptors within the gut. One would hope that this not-even-named compound would provide the benefits of Lotronex without the scary side effects that resulted in its being taken off the market.
...
Read Full Post
View the full article
...
Read Full Post
View the full article
